Lethiferous effects of a recombinant vector carrying thymidine kinase suicide gene on 2.2.15 cells via a self-modulating mechanism

World Journal of Gastroenterology

Volumn 9, Issue 10, 2003, Pages 2216-2220

  Kan, Quan Cheng ^a   Yu, Zu Jiang ^b   Lei, Yan Chang ^a   Hao, Lian Jie ^a   Yang, Dong Liang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; THYMIDINE KINASE;

ARTICLE; CELL CLONING; CELL STRAIN HEPG2; CELL SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUKARYOSIS; GENE CONSTRUCT; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; INTERNAL RIBOSOME ENTRY SITE; MORPHOLOGY; NONHUMAN; PHOTOGRAPHY; RECOMBINANT PLASMID; SUICIDE GENE; SUICIDE GENE THERAPY; SUPERNATANT; VIRUS CORE; VIRUS REPLICATION;

EID: 0142182293     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i10.2216     Document Type: Article

References (43)

1. Xu R, Cai K, Zheng D, Ma H, Xu S, Fan ST. Molecular therapeutics of HBV. Curr Gene Ther 2003; 3: 341-355
2. Morrissey DV, Lee PA, Johnson DA, Overly SL, McSwiggen JA, Beigelman L, Mokler VR, Maloney L, Vargeese C, Bowman K, O'Brein JT, Shaffer CS, Conrad A, Schmid P, Morrey JD, Macejak DG, Pavco PA, Blatt LM. Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA. J Viral Hepat 2002; 9: 411-418
3. Gumina G, Song GY, Chu GK. Advances in antiviral agents for hepatitis B virus. Antivir Chem Chemother 2001; 12(Suppl 1): 93-117
4. Feng Y, Kong YY, Wang Y, Qi GR. Intracellular inhibition of the replication of hepatitis B virus by hammerhead ribozymes. J Gastroenterol Hepatol 2001; 16: 1125-1130
5. Staschke KA, Colacino JM. Drug discovery and development of antiviral agents for the treatment of chronic hepatitis B virus infection. Prog Drug Res 2001; Spec No: 111-183
6. Harrison GL, Murray-McIntosh R, Penny D. Hepatitis B virus genotypes: A South Pacific perspective. Pac Health Dialog 2001; 8: 188-192
7. Zoulim F. Therapy of chronic hepatitis B virus infection: Inhibition of the viral polymerase and other antiviral strategies. Antiviral Res 1999; 44: 1-30
8. Merle P, Trepo C, Zoulim F. Current management strategies for hepatitis B in the elderly. Drugs Aging 2001; 18: 725-735
9. Bernardi M, Biselli M, Gramenzi A. Chronic hepatitis B. Recent advances in diagnosis and treatment. Recenti Prog Med 2002; 93: 397-402
10. Fang JN, Jin CJ, Cui LH, Quan ZY, Choi BY, Ki M, Park HB. A comparative study on serologic profiles of virus hepatitis B. World J Gastroenterol 2001; 7: 107-110
11. Rabe C, Pilz T, Klostermann C, Berna M, Schild HH, Sauerbruch T, Caselmann WH. Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroenterol 2001; 7: 208-215
12. Roussos A, Goritsas C, Pappas T, Spanaki M, Papadaki P, Ferti A. Prevalence of hepatitis B and C markers among refugees in Athens. World J Gastroenterol 2003; 9: 993-995
13. Liaw YF. Therapy of chronic hepatitis B: Current challenges and opportunities. J Viral Hepat 2002; 9: 393-399
14. Chin R, Locarnini S. Treatment of chronic hepatitis B: Current challenges and future directions. Rev Med Virol 2003; 13: 255-272
15. Karayiannis P. Hepatitis B virus: Old, new and future approaches to antiviral treatment. J Antimicrob Chemother 2003; 51: 761-785
16. Raj V. Treatment of hepatitis B. Clin Cornerstone 2001; 3: 24-36
17. Zoulim F, Trepo C. New antiviral agents for the therapy of chronic hepatitis B virus infection. Intervirology 1999; 42: 125-144
18. Klein C, Bock CT, Wedemeyer H, Wustefeld T, Locarnini S, Dienes HP, Kubicka S, Manns MP, Trautwein C. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 2003; 125: 9-18
19. Wo JE, Wu XL, Zhu HH, Zhou LF, Yao HP, Chen LW. DNAzymes in vitro inhibit the expression of hepatitis B virus genes. Zhejiang Daxue Xuebao Yixueban 2003; 32: 112-115
20. Tung FYT, Bowen SW. Targeted inhibition of hepatitis B virus gene expression: A gene therapy approach. Front Biosci 1998; 3: a11-a15
21. Guha C, Shah SJ, Ghosh SS, Lee SW, Roy-Chowdhury N, Roy-Chowdhury J. Molecular therapies for viral hepatitis. Bio Drugs 2003; 17: 81-91
22. Wu C, Zheng Z, Wang Q. Experimental study of inhibition of hepatitis B by dual-target antisense RNA. Zhonghua Yixue Zazhi 2001; 81: 605-608
23. Robaczewska M, Guerret S, Remy JS, Chemin I, Offensperger WB, Chevallier M, Behr JP, Podhajska AJ, Blum HE, Trepo C, Cova L. Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver. Gene Ther 2001; 8: 874-881
24. Feng Y, Kong YY, Wang Y, Qi GR. Inhibition of hepatitis B virus by hammerhead ribozyme targeted to the poly (A) signal sequence in cultured cells. Biol Chem 2001; 382: 655-660
25. Zu Putlitz J, Wieland S, Blum HE, Wands JR. Antisense RNA complementary to hepatitis B virus specifically inhibits viral replication. Gastroenterology 1998; 115: 702-713
26. Yang YS, Watson WJ, Tucker PW, Capra JD. Construction of recombinant DNA by exonuclease recession. Nucleic Acids Res 1993; 21: 1889-1893.
27. Horton RM. In vitro recombination and mutagenesis of DNA. SOEing together tailor-made genes. Methods Mol Biol 1997; 67: 141-149
28. Horton RM. PCR-mediated recombination and mutagenesis. SOEing together tailor-made genes. Mol Biotechnol 1995; 3: 93-99
29. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000; 81: 1631-1648
30. Reynolds JE, Kaminski A, Kettinen HJ, Grace K, Clarke BE, Carroll AR, Rowlands DJ, Jackson RJ. Unique features of internal initiation of hepatitis C virus RNA translation. EMBO J 1995; 14: 6010-6020
31. Morgan RA, Couture L, Elroy-Stein O, Ragheb J, Moss B, Anderson WF. Retroviral vectors containing putative internal ribosome entry sites: Development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res 1992; 25: 1293-1299
32. Lu HH, Wimmer E. Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus. Proc Natl Acad Sci 1996; 93: 1412-1417
33. Urabe M, Hasumi Y, Ogasawara Y, Matsushita T, Kamoshita N, Nomoto A, Colosi P, Kurtzman GJ, Tobita K, Ozawa K. A novel dicistronic AAV vector using a short IRES segment derived from hepatitis C virus genome. Gene 1997; 200: 157-162
34. Kruger M, Beger C, Li QX, Welch PJ, Tritz R, Leavitt M, Barber JR, Wong-Staal F. Identification of eIF2Bgamma and eIF2gamma as cofactors of hepatitis C virus internal ribosome entry site-mediated translation using a functional genomics approach. Proc Natl Acad Sci U S A 2000; 97: 8566-8571
35. Zhang H, Hanecak R, Brown-Driver V, Azad R, Conklin B, Fox MC, Anderson KP. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob Agents Chemother 1999; 43: 347-353
36. Liang XS, Lian JQ, Zhou YX, Nie QH, Hao CQ. A small yeast RNA inhibits HCV IRES mediated translation and inhibits replication of poliovirus in vivo. World J Gastroenterol 2003; 9: 1008-1013
37. Santolini E, Migliaccio G, La Monica N. Biosynthesis of biochemical properties of the hepatitis C virus core protein. J Virol 1994; 68: 3631-3641
38. Yasui K, Wakita T, Tsukiyama-Kohara K, Funahashi SI, Ichikawa M, Kajita T, Moradpour D, Wands JR, Kohara M. The native form and maturation process of hepatitis C virus core protein. J Virol 1998; 72: 6048-6055
39. Urabe M, Hasumi Y, Ogasawara Y, Matsushita T. Kamoshita N, Nomoto A, Colosi P, Kurtzman GJ, Tobita K, Ozawa K. A novel discistronic AAV vector using a short IRES segment derived from hepatitis C virus genome. Gene 1997; 200: 157-162
40. Shimoike T, Mimori S, Tani H, Matsuura Y, Miyamura T. Interaction of hepatitis C virus core protein with viral sense RNA and suppression of its translation. J Virol 1999; 73: 9718-9725
41. Zhang J, Yamada O, Yoshida H, Iwai T, Araki H. Autogenous translational inhibition of core protein: Implication for switch from translation to RNA replication in hepatitis C virus. Virology 2002; 293: 141-150
42. Li D, Takyar ST, Lott WB, Gowans EJ. Amino acids 1-20 of the hepatitis C virus (HCV) core protein specifically inhibit HCV IRES-dependent translation in HepG2 cells, and inhibit both HCV IRES- and cap-dependent translation in HuH7 and CV-1 cells. J Gen Virol 2003; 84: 815-825
43. Yao ZQ, Ray S, Eisen-Vandervelde A, Waggoner S, Hahn YS. Hepatitis C virus: Immunosuppression by complement regulatory pathway. Viral Immunol 2001; 14: 277-295